Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(04): 427-434
DOI: 10.1055/s-0042-1748829
Original Article

Expression of Neuron-Specific Enolase and Other Neuroendocrine Markers is Correlated with Prognosis and Response to Therapy in Non-Hodgkin Lymphoma

Somshankar Chowdhury 
1   Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
,
S.P Kataria
2   Department of Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
,
Amit Kumar Yadav
1   Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective Non-Hodgkin lymphoma (NHL) is a common hematological malignancy. There is very little known about the expression of neuroendocrine immunohistochemical markers and their clinical significance in NHL due to the paucity of studies. Our objective was to study the expression of neuroendocrine immunohistochemical markers in NHL and correlate with clinical parameters.

Materials and Methods All cases diagnosed as NHL on morphology and immunohistochemistry (World Health Organization, 2016 classification) were included in the study. Immunohistochemistry for neuron-specific enolase (NSE), synaptophysin, and chromogranin A was performed. The results were correlated with clinical parameters and response to chemotherapy.

Results A total of 66 cases were included in the study with a male-to-female ratio of 3.1:1. The most frequent subtypes observed were diffuse large B-cell lymphoma not otherwise specified and follicular lymphoma. Among the neuroendocrine markers, positivity was observed only for NSE, whereas the other markers were uniformly negative. It was positive in both B- and T-cell lymphomas and in many different subtypes. No relation with the age and sex of the patients was observed. However, NSE-positive cases, more frequently, presented in the advanced stage as compared with NSE negative (61 vs. 38%). All NSE-positive cases showed remission with chemotherapy.

Conclusion Among the neuroendocrine immunohistochemical markers, positivity was observed only for NSE. This isolated positivity suggests cross-binding of NSE antibodies with some other isoenzyme of NSE. NSE positivity was associated with higher stage and better response to therapy. Despite this apparent paradox, it is recommended that NSE should be part of routine immunohistochemical panel for NHL.

Keywords

Immunohistochemical markers - Lymphoma - Neuroendocrine - Neuron-specific enolase - Non-Hodgkin

Authors' Contributions

Amit Kumar Yadav contributed to the concept and design of this work, analysis of the data, writing of the manuscript, review of the final version of the submitted manuscript, and publication approval. Somshanker Chowdhury contributed to concept and design of this work, collection of data, analysis of the data, writing of the manuscript, review of the final version of the submitted manuscript, and publication approval. S.P. Kataria contributed to concept and design of this work, clinical data collection, analysis of the data, writing of the manuscript, review of the final version of the submitted manuscript, and publication approval.


Ethical Approval

The study has been conducted after taking institutional board approval.




Publication History

Article published online:
06 June 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Nair R, Arora N, Mallath MK. Epidemiology of non-Hodgkin's lymphoma in India. Oncology 2016; 91 (Suppl. 01) 18-25
    CrossrefPubMedGoogle Scholar
  • 2 Gazdar AF, Helman LJ, Israel MA. et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988; 48 (14) 4078-4082
    PubMedGoogle Scholar
  • 3 Hafezi-Bakthiari S, Mete O. The approach to metastatic endocrine tumors of unknown primary site. In: Mete O, Asa SL, eds. Endocrine Pathology. New York, NY:: Cambridge University Press;; 2016
    Google Scholar
  • 4 Kandalaft PL, Gown AM. Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch Pathol Lab Med 2016; 140 (06) 508-523
    CrossrefPubMedGoogle Scholar
  • 5 Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol 1984; 115 (03) 458-468
    PubMedGoogle Scholar
  • 6 Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 1986; 83 (10) 3500-3504
    CrossrefPubMedGoogle Scholar
  • 7 Ozçelik T, Lafreniere RG, Archer III BT. et al. Synaptophysin: structure of the human gene and assignment to the X chromosome in man and mouse. Am J Hum Genet 1990; 47 (03) 551-561
    PubMedGoogle Scholar
  • 8 McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, Südhof TC. Synaptophysin, a major synaptic vesicle protein, is not essential for neurotransmitter release. Proc Natl Acad Sci U S A 1996; 93 (10) 4760-4764
    CrossrefPubMedGoogle Scholar
  • 9 Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995; 58 (03) 65-88
    CrossrefPubMedGoogle Scholar
  • 10 Helman LJ, Ahn TG, Levine MA. et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem 1988; 263 (23) 11559-11563
    CrossrefPubMedGoogle Scholar
  • 11 Stadinski BD, Delong T, Reisdorph N. et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11 (03) 225-231
    CrossrefPubMedGoogle Scholar
  • 12 Rider CC, Taylor CB. Enolase isoenzymes in rat tissues. Electrophoretic, chromatographic, immunological and kinetic properties. Biochim Biophys Acta 1974; 365 (01) 285-300
    CrossrefPubMedGoogle Scholar
  • 13 Nemeth J, Galian A, Mikol J, Cochand-Priollet B, Wassef M, Lavergne A. Neuron-specific enolase and malignant lymphomas (23 cases). Virchows Arch A Pathol Anat Histopathol 1987; 412 (01) 89-93
    CrossrefPubMedGoogle Scholar
  • 14 Massarelli G, Onida GA, Piras MA, Marras V, Mura A, Tanda F. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas. Anticancer Res 1999; 19 (5B): 3933-3938
    Google Scholar
  • 15 Sandhu DS, Sharma A, Kumar L. Non-Hodgkin's lymphoma in Northern India: an analysis of clinical features of 241 cases. Indian J Med Paediatr Oncol 2018; 39 (01) 42-45
    Article in Thieme ConnectGoogle Scholar
  • 16 Straus DJ, Filippa DA, Lieberman PH, Koziner B, Thaler HT, Clarkson BD. The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969. Cancer 1983; 51 (01) 101-109
    CrossrefPubMedGoogle Scholar
  • 17 Anderson T, Chabner BA, Young RC. et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50 (12) 2699-2707
    CrossrefPubMedGoogle Scholar
  • 18 Elias L. Differences in age and sex distributions among patients with non-Hodgkin's lymphoma. Cancer 1979; 43 (06) 2540-2546
    CrossrefPubMedGoogle Scholar
  • 19 Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center. Ann Hematol 2012; 91 (10) 1603-1611
    CrossrefPubMedGoogle Scholar
  • 20 Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non- Hodgkin's lymphoma in India: a study of 2,773 lymphomas using REAL and WHO classification. Ann Oncol 2000; II (Suppl. 01) S63
    CrossrefGoogle Scholar
  • 21 Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013; 54 (05) 1004-1011
    CrossrefPubMedGoogle Scholar
  • 22 Sahni CS, Desai SB. Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma 2007; 48 (01) 122-133
    CrossrefPubMedGoogle Scholar
  • 23 Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978; 276 (5690): 834-836
    CrossrefPubMedGoogle Scholar
  • 24 O'Connor DT, Burton D, Deftos LJ, Chromogranin A. Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 1983; 33 (17) 1657-1663
    CrossrefPubMedGoogle Scholar
  • 25 Schmechel DE. Gamma-subunit of the glycolytic enzyme enolase: nonspecific or neuron specific?. Lab Invest 1985; 52 (03) 239-242
    Google Scholar
  • 26 Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985; 52 (03) 257-263
    Google Scholar
  • 27 Wang L, Liu P, Geng Q, Chen X, Lv Y. Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Leuk Lymphoma 2011; 52 (09) 1697-1703
    CrossrefPubMedGoogle Scholar
  • 28 Bilgin E, Dizdar Y, Serilmez M. et al. For which cancer types can neuron-specific enolase be clinically helpful in Turkish patients?. Asian Pac J Cancer Prev 2013; 14 (04) 2541-2544
    CrossrefPubMedGoogle Scholar
  • 29 Wang L, Liu P, Chen X, Geng Q, Lu Y. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol 2012; 29 (03) 2153-2158
    CrossrefPubMedGoogle Scholar
  • 30 Takahashi K, Goi K, Satou H. et al. [NSE-positive lymphoblastic lymphoma in a boy with cutaneous involvement, giant splenomegaly, and hyper-gamma globulinemia]. Rinsho Ketsueki 2004; 45 (12) 1247-1251
    PubMedGoogle Scholar
  • 31 Nakatsuka S, Nishiu M, Tomita Y. et al. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL). Jpn J Cancer Res 2002; 93 (04) 411-416
    CrossrefPubMedGoogle Scholar
  • 32 Yamaguchi K, Nishimura Y, Asou N. et al. Elevated serum levels of neuron specific enolase in lymphoid leukaemia. Leuk Lymphoma 1990; 1 (5-6): 335-340
    CrossrefPubMedGoogle Scholar
  • 33 Liu CC, Wang H, Wang JH. et al. Serum neuron-specific enolase levels are upregulated in patients with acute lymphoblastic leukemia and are predictive of prognosis. Oncotarget 2016; 7 (34) 55181-55190
    CrossrefPubMedGoogle Scholar
  • 34 Yang H, Mi R, Wang Q. et al. Expression of neuron-specific enolase in multiple myeloma and implications for clinical diagnosis and treatment. PLoS One 2014; 9 (05) e94304
    CrossrefPubMedGoogle Scholar